Eli Lilly and Company
Eli Lilly Announces Retirement of Board Member Dr. Marschall S. Runge
Summary
Eli Lilly and Company announced on August 16, 2024, the retirement of Dr. Marschall S. Runge from its Board of Directors, effective August 31, 2024. Dr. Runge, who has served on the board since 2013, will retire from his leadership roles at Michigan Medicine by June 30, 2025, but will remain a professor at the University of Michigan Medical School. His retirement marks the end of a decade of valuable service, during which he provided critical insights into science, medical affairs, and patient care, contributing significantly to Lilly's mission to improve global health.
Profitelligence Alerts
Get alerts for LLY
Be first to know when Eli Lilly and Company files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Eli Lilly and Company
Eli Lilly and Company is a renowned pharmaceutical corporation that engages in the discovery, development, manufacturing, and marketing of pharmaceutical products worldwide. The company's core purpose is to create high-quality medications that address significant medical needs in areas such as oncology, immunology, neuroscience, and endocrinology. Eli Lilly is particularly noted for its pioneering work in diabetes care with products like insulin and for its innovative approach to treating complex health conditions. With a history dating back to 1876, the Indianapolis-based company blends scientific innovation with a commitment to improve patient outcomes. Eli Lilly’s role in the financial markets is significant due to its contributions to healthcare advancements and its influence on global pharmaceutical trends. The company's robust pipeline and emphasis on research and development underscore its potential to impact healthcare solutions and deliver sustainable growth. Its products and services are marketed globally, underlying its importance in the biopharmaceutical industry.
Official SEC Documents
Advertisement